Many studies have further shown that even when cancers progress after trastuzumab therapy, ErbB2 still remains a valid therapeutic target [17–20], suggesting that ErbB2 still represents a major vulnerability for ErbB2-positive cancer cells [21]. This evidence concerns the gene ERBB2 and cancer.